Jan 23, 2020

Blues plans invest in new generic drug company

A new company will sell generic medicines at cost. Photo: George Frey/Getty Images

Eighteen Blue Cross Blue Shield insurers are investing a combined $55 million to build a new generic drug company as a subsidiary of the nonprofit Civica Rx. The firm will focus on manufacturing generics people get at the pharmacy.

Between the lines: Civica and the Blues aren't disclosing which drugs they want to make, so it's unclear how much effect this company will have. But the investment highlights the broad desire to counter generic companies that are accused of price-gouging.

What they're saying: The new company is evaluating a list of 30 to 40 generic drugs that have little or no competition and are deemed to be "high-priced," Civica CEO Martin VanTrieste said.

  • "If you're in the supply chain and you're causing that artificially high price, you should be concerned," VanTrieste said.

Yes, but: Pharmacies have contracts with wholesalers that usually require them to buy a vast majority of their drugs from that wholesaler.

  • Veering outside of that system, even to get cheaper drugs, may not be easy, and may not guarantee quick access to those drugs.
  • However, the Blues plans are now trying to recruit retailers and pharmacies to join and buy the generics that will start rolling out in 2022.

The bottom line: Civica has already started distributing hospital-based drugs. This effort similarly hinges on which drugs are targeted and how cheap Civica's new subsidiary can make them.

Go deeper

FDA defends its drug approval process after controversial reviews

FDA headquarters. Photo: Al Drago/CQ Roll Call

Many experts have questioned the FDA's drug approval standards over the past few years, as several controversial drugs have gotten the green light despite less rigorous testing.

What they're saying: Peter Stein, the head of the FDA's office that analyzes new drugs, sat down with Zachary Brennan of Regulatory Affairs Professionals Society and said the only thing that's changed with the FDA's approval process is a shift in the types of drugs the agency is reviewing.

Go deeperArrowFeb 11, 2020 - Health

Why Biogen's generic drug patent win matters

Mylan is itching to make a generic version of Biogen's popular multiple sclerosis drug Tecfidera, but that won't be happening for a while now that federal patent reviewers turned down Mylan's patent challenge.

The big picture: The victory for Biogen not only secures several more years of monopoly pricing for the company — Biogen has a history of raising Tecfidera's list price by at least 5% per year — but also likely will create a higher baseline price for when Tecfidera generics finally come out.

Go deeperArrowFeb 10, 2020 - Health

Coronavirus outbreak fuels concerns about pharma's global supply chain

A medical worker walks out of a hospital in Wuhan, China, on Jan. 27. Photo: Feature China/Barcroft Media via Getty Images

The spread of the coronavirus in China has raised concerns about the pharmaceutical industry's global supply chain, STAT reports.

Between the lines: China produces a large portion of the ingredients used to make drugs. As the coronavirus spreads and sends China increasingly into lockdown, it's causing experts to question whether the supply chain is stable.

Go deeperArrowJan 28, 2020